Randomized phase II trial of daily administration versus alternate-day administration of S-1 in patients with advanced non-small cell lung cancer

Cancer Statistics in Japan-2014. Center for Cancer Control and Information Services, National Cancer Center. Shepherd, 2000, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J. Clin. Oncol., 18, 2095, 10.1200/JCO.2000.18.10.2095 Hanna, 2004, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J. Clin. Oncol., 22, 1589, 10.1200/JCO.2004.08.163 Scagliotti, 2009, The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies, Oncologist, 14, 253, 10.1634/theoncologist.2008-0232 Shirasaka, 1996, Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators, Anticancer Drugs, 7, 548, 10.1097/00001813-199607000-00010 Sakuramoto, 2007, ACTS-GC Group, Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine, N. Engl. J. Med., 357, 1810, 10.1056/NEJMoa072252 Lipkin, 1963, Cell proliferation kinetics in the gastrointestinal tract of man, Gastroenterology, 45, 721, 10.1016/S0016-5085(19)34805-X Clarkson, 1965, Kinetics of proliferation of cancer cell in neoplastic effusions in man, Cancer, 18, 1189, 10.1002/1097-0142(196510)18:10<1189::AID-CNCR2820181002>3.0.CO;2-8 Arai, 2004, Alternate-day oral therapy with TS-1 for advanced gastric cancer, Int. J. Clin. Oncol., 9, 143, 10.1007/s10147-004-0381-9 Sakuma, 2010, Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity, Int. J. Clin. Oncol., 15, 166, 10.1007/s10147-010-0036-y Koizumi, 2008, S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial, Lancet Oncol., 9, 215, 10.1016/S1470-2045(08)70035-4 Boku, 2009, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study, Lancet Oncol., 10, 1063, 10.1016/S1470-2045(09)70259-1 Narahara, 2011, Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002), Gastric Cancer, 14, 72, 10.1007/s10120-011-0009-5 Simon, 1985, Randomized phase II clinical trials, Cancer Treat. Rep., 69, 1375 Kubota, 2015, Tokyo Cooperative Oncology Group, A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plur cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial, Ann. Oncol., 26, 1401, 10.1093/annonc/mdv190 Okamoto, 2010, Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a West Japan Oncology Group study, J. Clin. Oncol., 28, 5240, 10.1200/JCO.2010.31.0326 Kawahara, 2001, S-1 Cooperative Study Group (Lung Cancer Working Group), Br. J. Cancer., 85, 939, 10.1054/bjoc.2001.2031 Nishio, 2016, Randomized controlled trial of S-1 versus docetaxel in patients with non-small cell lung cancer who have received a platinum-based treatment (EAST-LC), Ann. Oncol., 27, vi416, 10.1093/annonc/mdw383.18 T. Shirasaka, S. Yamamitsu, A. Tsuji, T. Taguchi, Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to anovel oral fluororimidine prodrug, S-1, and low-dose FP therapy in Japan, Invest. New Drugs, 18(200) 315–329. Shirasaka, 2000, Conceptual changes in cancer chemotherapy-biochemical modulation of 5-FU from bench to clinic, Gan to Kagaku Ryoho, 20, 193 Arai, 2008, Comparison of alternate-day versus consective-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo, Int. J. Clin. Oncol., 13, 515, 10.1007/s10147-008-0780-4 Yamaue, 2017, Multicenter, Randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer, Cancer Chemother. Pharmacol., 79, 813, 10.1007/s00280-017-3250-8